Navigation Links
Test for Esophageal Reflux Licensed to Bayer by University

A new test for esophageal reflux disease developed by a Wake Forest University Health Sciences (WFUHS) otolaryngologist has been licensed to Bayer HealthCare’s Diagnostics Division by WFUHS.//

The test, which detects the presence of human pepsin 3b in a patient’s saliva, was developed by Jamie Koufman, M.D., then professor of otolaryngology at Wake Forest University School of Medicine and director of WFUHS’s Center for Voice Disorders. She is now director of the Voice Institute of New York.

The test potentially could be used in the offices of primary care physicians and avoid the need for more elaborate and expensive tests. Bayer will market the test.

“Most people associate heartburn with excess stomach acid, but it is the digestive enzyme pepsin (and not acid) bathing the lower area of the esophagus that causes the damage,” said Koufman. “For patients with severe esophagitis, the tissue in the esophagus is literally being self-digested.”

“Besides helping to diagnose gastroesophageal reflux disease, or ‘GERD,’ detecting pepsin in saliva also should help diagnose laryngopharyngeal reflux disease, the backflow of stomach contents into the throat,” she said. “Laryngopharyngeal reflux disease is even more difficult to diagnose than GERD. Scientific evidence points to aerosolized pepsin being drawn into the respiratory system as a common culprit of chronic cough, asthma, and even sinusitis.”

Dean Stell, associate director of the Office of Technology Asset Management, said, “Bayer is a world leader in point-of-care diagnostics and is well qualified to handle the next stage of development. That is the essence of technology transfer – working with our industrial counterparts who can develop technology in ways that we cannot.”

Stell added that the licensing step was “a milestone following 25 years of research, and lots of hard work by Dr. Koufman and the people on her team.”

Since 1981, Koufman has done pio
'"/>




Page: 1 2

Related medicine news :

1. Soft Drinks May Reduce Esophageal Cancer Risk
2. PET Can Predict Response To Treatment In Esophageal Cancer Patients
3. Hiccups May Be An Indication Of Esophageal Cancer
4. Studies Find Connection Between Acid Reflux And Esophageal Cancer
5. Rise in Esophageal Cancer is emphasized by Richards’ deat
6. Esophageal Cancer Rates Climb With Obesity
7. The Causes Of Acid Reflux Questioned
8. Acid Reflux Increases Risk Of Esophagus Cancer
9. Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity
10. New Reflux Disease Technology More Comfortable, Not More Effective
11. Studies Find Connection Between Acid Reflux And Esophageal Cancer
Post Your Comments:
(Date:7/3/2009)... July 3 Bertalan Mesko, medical bl...e e-guide for medical professionals focusing on ...dical conferences are expensive and patients are a...is eGuide helps doctors enter a virtual realm and ...ee as Second Life provides opportunities for case ...
(Date:7/3/2009)... Republicans on the Sen...health care reform legislation that would eliminat... many women could lose coverage for abortion servi...s. Plus, millions of uninsured women will still la... promised a better quality of life. , , If thes...
(Date:7/3/2009)... ReverseAges.com launches new content to includ...atigue, and how to best deal with these health iss...EB) July 3, 2009 -- ReverseAges.com has recently l... the dangers of common health issues such as high ... variety of factors, and the new content on Revers...
(Date:7/2/2009)...ore,s Bioprocessing Technology Institute (BTI) hav...apoptosis inhibitory molecule" (FAIM), protects bo...ammed cell death. , Their research is published...ation . , The scientists, Jianxin Huo, Ph.D., an...cess may possibly be manipulated for clinical appl...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2
...that practitioners don’t have to use a lot of forc...ponse // as the body has its own energy or "biomag... system. That field can be altered by acupuncture ...opathy, massage, and even by the therapists' own p...
...e might be another use for cell phones that come c...ations.// Swiss researchers who used the phone cam...remote locations say doctors felt fairly comfortab...s. The study involved 52 patients with 61 chronic ...
...tudy researchers say a three-day regimen of the an...t as effective // as ciprofloxacin (Cipro) at trea...The most common bacterial infections for women are...tions. Treating the problem has become increasingl...
... now that after delivery depressions, that had pla... due to the trauma of the delivery. As a result of...ned caesarian birth to avoid the depression. A new... British Medical Journal says that this may not be...
Other Medicine News:
(Date:6/30/2009)...., June 30 Cephalon, Inc...bmitted a supplemental New Drug Application (sNDA)...questing approval of NUVIGIL(R) (armodafinil) Tabl...ess in patients with excessive sleepiness associat...travel. Jet lag disorder is an acute condition th...
(Date:6/29/2009)...ajor abdominal surgery patients achieved primary a..., June 29 AcelRx Pharmaceuticals, ...ond Phase 2 clinical study evaluating the safety a...for the management of acute post-operative pain in...alization. Compared to placebo, patients receiving...
(Date:6/28/2009)...NHAM, England and TOKYO, June 29 ,... Companies , Sosei Group Corporation ("Sose...c ("Vectura"; LSE: VEC) announce the commencement ...VA237, a once-daily, long-acting muscarinic,antag...ive pulmonary disease,(COPD). NVA237 is a dry pow...
(Date:6/26/2009)...pinion Recommends Approval of New Anti-TNF Therapy...TM) Autoinjector , , HORSHAM, Pa. and KENILWORT...r Ortho Biotech Inc. and Schering-Plough Corporati...ee for Medicinal Products for Human Use (CHMP) of ...itive opinion recommending the approval of SIMPONI...
Breaking Medicine Technology:Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Vermont Surgeon Implants First Accommodating Crystalens in Russia 9146 1Vermont Surgeon Implants First Accommodating Crystalens in Russia 9146 2PLC Systems Updates Common Stock Listing Status 29620 1PLC Systems Updates Common Stock Listing Status 29620 2Soft Contact Lenses Do Not Lead to Myopic Creep in Children Study Shows 3438 1Soft Contact Lenses Do Not Lead to Myopic Creep in Children Study Shows 3438 2Soft Contact Lenses Do Not Lead to Myopic Creep in Children Study Shows 3438 3Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures 29614 1Advanced Imaging Technologies to Limit Breast and GI Biopsy Procedures 29614 2
...Investigational cancer drug Pertuzumab shows promi...ed with Herceptin Phase III,development initiated,...esults from,Roche,s trial of the exciting new canc...or, show substantial anti-tumour activity in,patie...when,combined with Herceptin. The study showed tha...
...- First Agent Ever to Demonstrate Significant Surv...2007 /PRNewswire-FirstCall/ -- Bayer,HealthCare Ph...today announced that Nexavar(R) (sorafenib) tablet...nts with hepatocellular carcinoma,(HCC), or primar...(HR=0.69; p-value=0.0006). Results were presented ...
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7
Double round silicone drain with trocar, 49 in. long, with 12.25 in. (30.5 cm) hole pattern
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe.
Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte
Used for cholangiography and bile stone removal using fluoroscopy. Dual lumen catheter design allows concomitant fluoroscopic biliary imaging and wire basket placement for stone extraction. Supplied
Medicine Products: